IASLC TTLC 2024 | Combination therapies involving KRAS G12C inhibitors in lung cancer

Alexander Spira, MD, Next Oncology-Virginia VCS, Fairfax, VA, discusses novel KRAS G12C inhibitor combination therapies for patients with lung cancer. In addition to trialing KRAS G12C inhibitors in the frontline setting, combination therapies including sotorasib or adagrasib are being investigated. Novel KRAS inhibitors including RMC-6236 and VS-6766 are also in development. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.